
Join 900 US CEOs protest against Ukraine invasion
As Russia continues its unprovoked war on Ukraine, the U.S. life sciences community is united in its total rejection of the criminal actions taken by...

AXA launches €440 m private equity healthcare strategy
The Strategy focuses specifically on companies in four core areas: medical devices, biopharmaceuticals, vaccines, and diagnostics. The...

Study shows advantages of cellular agriculture
Replacing animal-source foods (ASFs) with novel or future foods (NFFs) – such as cultured milk, insect meal or mycoprotein – or plant-based...

Bayer invests into synthetic TCRs for cell therapy
Sometimes it's not bad to have old contacts like Jak Knowles, CEO of Boston-based Affini-T Therapeutics Inc., which left stealth mode at the J.P....

Gilde Healthcare Private Equity IV launches €517m
The new oversubscribed fund will focus its investements on firms with an active buy-and-build strategy and is designed to invest in all sub-segments...

Hansa Biopharma’s imlifidase advances to Phase III testing
According to Lund-based Hansa Biopharma AB the study protocol has been greenlighted both by the FDA and the European Medicines Agency (EMA), so its...

Single-use market to reach $20.8bn by 2026
The "Global Forecast 2026" comprises Media Bags and containers, Bioreactors, Mixers, Assemblies, Applications (Cell Culture, Mixing,...